Bionano Genomics, Inc. (BNGO)

Bionano Genomics, Inc. (BNGO) Healthcare & Pipeline Overview

Bionano Genomics, Inc. offers genome analysis software and the Saphyr system, enabling structural variation analysis via optical genome mapping. Targeting the diagnostics and research sectors, Bionano provides tools for understanding genetic variation and function, though it operates in a competitive and evolving market landscape.

What Is the Investment Thesis for BNGO?

Bionano Genomics operates in the rapidly evolving field of genomics, with a focus on structural variation analysis. The company's Saphyr system offers a unique approach to visualizing and analyzing DNA structure, potentially providing valuable insights in research and clinical diagnostics. However, with a negative profit margin of -109.9% and a market capitalization of $13.31M, the company faces significant challenges in achieving profitability and scaling its operations. Growth catalysts include expanding the adoption of OGM in clinical settings and developing new applications for the Saphyr system. The company's success hinges on its ability to demonstrate the clinical utility of its technology and secure reimbursement for its diagnostic tests.

Based on FMP financials and quantitative analysis

BNGO Key Highlights

• Bionano Genomics operates with a small team of 98 employees, indicating a lean organizational structure.
• The company's gross margin stands at 47.0%, suggesting a reasonable ability to control the cost of goods sold.
• Bionano Genomics has a beta of 1.62, indicating higher volatility compared to the overall market.
• The company's profit margin is -109.9%, reflecting significant losses and a need to improve profitability.
• Bionano Genomics does not currently offer a dividend, which is typical for growth-oriented companies in the biotechnology sector.

Who Are BNGO's Competitors?

BNGO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BNGO's Key Strengths?

• Unique optical genome mapping (OGM) technology.
• Integrated system of hardware, software, and consumables.
• Expertise in structural variation analysis.
• Established customer base in research and clinical settings.

What Are BNGO's Weaknesses?

• Negative profit margin and limited financial resources.
• Smaller market presence compared to larger competitors.
• Reliance on a single technology platform.
• Need to demonstrate clinical utility and secure reimbursement.

What Could Drive BNGO Stock Higher?

• Publication of clinical studies demonstrating the utility of OGM in specific diseases.
• Regulatory approvals for Bionano's diagnostic tests.
• Expansion of the Saphyr installed base.
• Development of new applications for OGM.
• Strategic partnerships with research institutions and pharmaceutical companies.

What Are the Key Risks for BNGO?

• Financial-distress signal — its Altman Z-Score of -16.25 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-71.4%) — the business is not currently generating profit on shareholder capital.
• Competition from established technologies like next-generation sequencing (NGS).
• Regulatory hurdles and reimbursement challenges.
• Technological obsolescence.
• Negative profit margin and limited financial resources.
• Dependence on a single technology platform.

What Are the Growth Opportunities for BNGO?

• Expansion into Clinical Diagnostics: Bionano has the opportunity to expand the use of its Saphyr system in clinical diagnostics. The structural variation analysis provided by OGM can be valuable in diagnosing genetic diseases and cancer. Securing regulatory approvals and reimbursement for its diagnostic tests is crucial for realizing this growth opportunity. The market for genetic testing is projected to reach $25 billion by 2028, providing a significant opportunity for Bionano.
• Development of New Applications: Bionano can drive growth by developing new applications for its Saphyr system. This includes exploring the use of OGM in areas such as drug discovery, personalized medicine, and agricultural genomics. By expanding the applications of its technology, Bionano can reach new markets and customers. The market for personalized medicine is expected to reach $2.4 trillion by 2030, offering a substantial growth opportunity.
• Strategic Partnerships and Collaborations: Forming strategic partnerships and collaborations with research institutions, pharmaceutical companies, and clinical laboratories can accelerate the adoption of Bionano's technology. These partnerships can provide access to new markets, funding, and expertise. Collaborating with leading researchers can also help validate the clinical utility of OGM and drive its adoption in clinical practice. The market for research collaborations is growing, with increasing demand for innovative genomic analysis tools.
• Geographic Expansion: Bionano has the opportunity to expand its geographic reach by targeting new markets in Asia, Europe, and Latin America. These regions offer significant growth potential, particularly in countries with rapidly developing healthcare systems. Establishing a presence in these markets requires building a strong sales and marketing infrastructure and adapting its products to local needs. The global market for genomic analysis is expanding, with emerging markets offering particularly attractive growth opportunities.
• Advancements in OGM Technology: Continuous innovation in optical genome mapping (OGM) technology can enhance the performance and capabilities of the Saphyr system. This includes improving the resolution, throughput, and automation of OGM. By staying at the forefront of OGM technology, Bionano can maintain its competitive advantage and attract new customers. The market for advanced genomic analysis tools is driven by technological innovation, with continuous demand for improved performance and capabilities.

What Opportunities Does BNGO Have?

• Expansion into clinical diagnostics.
• Development of new applications for OGM.
• Strategic partnerships and collaborations.
• Geographic expansion into emerging markets.

What Threats Does BNGO Face?

• Competition from next-generation sequencing (NGS) technologies.
• Regulatory hurdles and reimbursement challenges.
• Technological obsolescence.
• Economic downturn and reduced research funding.

What Are BNGO's Competitive Advantages?

• Proprietary optical genome mapping (OGM) technology.
• Established customer base in research and clinical settings.
• Integrated system of hardware, software, and consumables.
• Expertise in structural variation analysis.

What Does BNGO Do?

Founded in 2003 and headquartered in San Diego, California, Bionano Genomics, Inc. is a genome analysis company focused on developing and marketing the Saphyr system, a platform for structural variation analysis. The company's core technology, optical genome mapping (OGM), allows researchers and clinicians to visualize and analyze the structure of DNA, providing insights into genetic diseases and cancer. Bionano's product portfolio includes the Saphyr instrument, single-molecule imager, Saphyr Chips (consumables for DNA linearization), and Bionano Prep Kits and DNA labeling kits. These kits provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA, essential for OGM. In addition to hardware and consumables, Bionano offers software solutions like NxClinical, which facilitates the analysis and interpretation of genomic variants from microarray and next-generation sequencing data. Bionano also provides testing and laboratory services, including FirstStepDx PLUS for autism spectrum disorder, Fragile X syndrome (FXS) testing, NextStepDx PLUS for childhood development disorders, EpiPanelDx PLUS for seizure-related disorders, and PGx testing for pharmacogenomics. Bionano's solutions are used in cytogenetics and molecular genetics, supporting research and clinical applications.

What Products and Services Does BNGO Offer?

• Provides the Saphyr system for optical genome mapping (OGM).
• Offers consumables like Saphyr Chips and Bionano Prep Kits.
• Develops software solutions for genomic variant analysis (NxClinical).
• Offers laboratory testing services for genetic disorders.
• Provides tools for structural variation analysis in DNA.
• Supports research and clinical applications in cytogenetics and molecular genetics.

How Does BNGO Make Money?

• Sales of Saphyr instruments to research institutions and clinical laboratories.
• Recurring revenue from the sale of consumables (Saphyr Chips and Bionano Prep Kits).
• Software licensing fees for NxClinical.
• Revenue from laboratory testing services.
• Partnerships and collaborations with research organizations and pharmaceutical companies.

What Industry Does BNGO Operate In?

Bionano Genomics operates within the medical diagnostics and research industry, a sector characterized by rapid innovation and increasing demand for advanced genomic analysis tools. The market for structural variation analysis is growing as researchers and clinicians seek to better understand the role of genomic variations in disease. Bionano competes with companies offering next-generation sequencing (NGS) and microarray-based solutions. The company's optical genome mapping (OGM) technology offers a unique approach to structural variation analysis, but it faces the challenge of demonstrating its clinical utility and competing with established technologies.

Who Are BNGO's Key Customers?

• Research institutions conducting genomic research.
• Clinical laboratories performing genetic testing.
• Pharmaceutical companies involved in drug discovery and development.
• Hospitals and healthcare providers offering genetic diagnostics.
• Academic centers studying genetic disorders.

Company Profile

Bionano Genomics, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in San Diego, US. The company is led by CEO Robert Erik Holmlin. BNGO has traded publicly since 2018.

Bionano Genomics, Inc. Financial Trajectory

Bionano Genomics, Inc. (BNGO) reported $6.7M in revenue for Q1 2026, a decline of 15.9% compared to the prior quarter. The company recorded a net loss of $8.3M, with diluted EPS of $-0.76. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, BNGO averaged $-1.45 in diluted EPS.

How Bionano Genomics, Inc. Is Valued

Bionano Genomics, Inc. carries a market capitalization of $13.31M, placing it in the micro-cap category. Relative to its peer group, BNGO's quantitative score of 18/100 is below the peer average of 74/100.

ROE -71%Key Financial Metrics

Return on equity for Bionano Genomics, Inc. stands at -71.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -48.8%, showing how much profit it generates from its asset base. A current ratio of 1.84 indicates the company holds enough short-term assets to cover its near-term obligations.

F-Score 4/9Financial Health

Bionano Genomics, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -16.25 places it in the distress zone, a signal of elevated financial risk.

FY2026 estForward Outlook

Wall Street analysts project Bionano Genomics, Inc. revenue of about $32.1M for fiscal 2026, with EPS near $-2.31.

BNGO Financials

BNGO Latest News

BNGO Analyst Consensus

BNGO MoonshotScore

BNGO Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources